Angion Biomedica (ANGN) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	301K
Depreciation and amortization
Stock-based compensation	523K
(Decrease) increase in allowance for doubtful accounts	-18K
(Decrease) increase in inventory obsolescence reserve
Loss on disposal of equipment	2K
Accounts receivable	950K
Inventories	-173K
Prepaid expenses and other current assets	384K
Accounts payable	-297K
Employee compensation	-317K
Deferred income	966K
Warranty reserve
Other current liabilities and accrued expenses	-560K
Net cash (used in) provided by operating activities
Sales (purchases) of investments
Purchases of property and equipment and intangible assets	-697K
Net cash provided by (used in) investing activities
Proceeds from issuance of common stock under employee stock purchase plan	97K
Proceeds from the exercise of stock options
Repurchase of common stock
Repurchase of common stock upon vesting of restricted stock grants
Net cash used in financing activities
Net increase (decrease) in cash and cash equivalents	-781K
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period

Entities mentioned with ANGN

View All Entities